Let me say first, I am not kinda ‘well-planned’ person! But, I am been inspired to become planned from my radio co-host Ali! As learnt – preparation is key. I know lots of people shy away from planners or weekly diaries and many have taken … Continue reading
Can chronic stress cause depression? A new study in mice adds important evidence that it can, and sheds light on how antidepressants work. The new research, published in Nature, builds on earlier studies showing that chronic high stress kills neurons and prevents … Continue reading
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.(1) The FDA has approved linagliptin as a monotherapy or in combination with other commonly prescribed medications for type (2) diabetes—such as metformin, sulphonylurea and pioglitazone – to reduce haemoglobin A1c (HbA1c or A1c) levels by a mean of up to -0.7 percent (compared to placebo).(2) HbA1c is measured in people with diabetes to provide an index of blood sugar control for the previous two to three months. It is used as a marker of efficacy of antihyperglycaemic therapies.
Linagliptin belongs to a class of prescription medications called dipeptidyl peptidase-4 (DPP-4) inhibitors and is the first member of its class to be approved at one dosage strength (5 mg, once daily).(1) With linagliptin, no dose adjustment is recommended for patients with kidney or liver impairment. Linagliptin is a tablet that can be taken with or without food. Linagliptin lowers blood sugar in a glucose-dependent manner by increasing incretin levels (GLP-1), which increase insulin levels after meals and throughout the day.(1)
“Many people with type 2 diabetes are not able to control their blood sugar with diet and exercise alone and may also require one or more medications,” said John Gerich M.D., Professor of Medicine, University of Rochester School of Medicine. “The FDA approval of linagliptin is exciting because there is only Continue reading